Physician profile
Nesreen Suwan
NPI 1821095936
$191,502.21
in general payments reported to CMS, 2019-2025
43 companies · $9,863 in 2025
The $9,863 reported for 2025 was more than what 89% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $943 · 2020: $18K · 2021: $40K · 2022: $67K · 2023: $42K · 2024: $13K · 2025: $9,863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $55K · Travel and Lodging: $5,318 · Food and Beverage: $4,836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $54,612.50 |
| Travel and Lodging | $5,318.28 |
| Food and Beverage | $4,835.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $124,683.25 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Biohaven Pharmaceutical Holding Company Ltd. | $31,297.20 | 2022 | |
| Allergan, INC. | $20,889.90 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $7,296.59 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $2,893.12 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Lilly USA, LLC | $1,049.78 | 2019-2025 | Zepbound, Mounjaro, Amyvid |
| Novo Nordisk INC | $428.94 | 2020-2025 | Wegovy |
| Lundbeck LLC | $362.99 | 2020-2025 | Vyepti |
| Scilex Pharmaceuticals INC. | $282.46 | 2020-2025 | |
| Biogen, INC. | $213.66 | 2021-2025 | Tysabri, Vumerity, Avonex |
| Alexion Pharmaceuticals, INC. | $189.20 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $180.05 | 2020-2022 | |
| Horizon Therapeutics Plc | $154.52 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $131.36 | 2024 | Gvoke Hypopen |
| Aimmune Therapeutics, INC. | $125.00 | 2024 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nesreen Suwan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.